Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548000 | 0.84 | NPC1 (0.75) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL3811713 | 0.84 | TDP1 (0.54) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL3514013 | 0.84 | MAPT (0.53) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL1924834 | 0.84 | RAB9A (0.51) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL4845394 | 0.83 | TDP1 (0.53) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL10477058 | 0.83 | MAPT (0.52) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL29382840 | 0.83 | NPC1 (0.54) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL2833379 | 0.83 | NPC1 (0.54) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL3484477 | 0.83 | ALDH1A1 (0.52) | RAB9ARECQLNPC1ALDH1A1MAPT | |
| SCHEMBL3514222 | 0.82 | MAPT (0.51) | RAB9ARECQLNPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723329-B2 | Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| EP-2004659-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080280893-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280893-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280893-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2008-11-13 | — | — | US | disclosed |
| US-7414051-B2 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414051-B2 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414051-B2 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1931640-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007120594-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120594-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-HI]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070244106-A1 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244106-A1 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244106-A1 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021711-A2 | SUBSTITUTED-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | WYETH (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280893-A1 | SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, HTR5A, HTR2C | RAB9A 3836/4885RECQL 2526/4885NPC1 1963/4885 |
| US-20070037802-A1 | such as N,N-Dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy}propan-1-amine, used for the treatment of a central nervous system disorders | HTR6, TPH1, HTR1A | RAB9A 3414/4885RECQL 2544/4885NPC1 478/4885 |
| US-20070244106-A1 | Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | RAB9A 3836/4885RECQL 2526/4885NPC1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.